<DOC>
	<DOCNO>NCT00504257</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness combination Avastin Docetaxel treatment woman platinum sensitive recurrent epithelial ovarian cancer within 12 month platinum chemotherapy .</brief_summary>
	<brief_title>Avastin Combination With Docetaxel Ovarian/Fallopian Tube/Peritoneum Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Signed informed consent Pathologically confirm epithelial ovarian cancer , peritoneal serous cancer , fallopian tube cancer Patient 's disease recurrence progression occur 0 12 month ( 1 365 day ) prior platinumcontaining chemotherapy regimen . Patients , however , may receive study drug least 28 day prior chemotherapy . The patient may receive three prior chemotherapy regimens treatment malignancy . Patients may receive prior treatment paclitaxel and/or platinum compound allow . Rechallenge platinum base regimen consider 1 prior regimen . Patients treated consolidation treatment allow consolidation consider separate regimen . Hormonal therapy ( i.e . progesterone , estrogen , antiestrogens , aromatase inhibitor ) consider prior chemotherapy regimen . Measurable evaluable disease either Gynecologic Oncology Group ( GOG ) Response Evaluation Criteria Solid Tumors ( RECIST ) cancer antigen ( CA ) 125 criterion [ Journal National Cancer Institute ( JNCI ) , Vol . 96 , No . 6 , March 17 , 2004 , Vergote JNCI 2000 ] At least 4 week since major surgery , full recovery At least 3 week since radiotherapy , full recovery . The measurable disease must completely outside radiation port . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; /= 2 Hematologic ( minimal value ) : Absolute neutrophil count &gt; /= 1,500/mm^3 , Hemoglobin &gt; /= 8.0 g/dL ( transfusion allow ) , Platelet count &gt; /= 100,000/mm^3 Hepatic : Total Bilirubin &lt; /= upper limit normal ( ULN ) , alanine transaminase ( AST ) alanine transaminase ( ALT ) alkaline phosphatase must within range allow eligibility . In determine eligibility abnormal 2 value ( AST ALT ) use . Women childbearing potential must negative pregnancy test . Patients childbearing potential must willing consent use effective contraception treatment 3 month follow completion treatment . Prior treatment Docetaxel Avastin Concurrent immunotherapy hormonal therapy specific purpose treatment ovarian cancer . Any hormonal therapy direct malignant tumor must discontinue least one week prior enrollment order patient eligible participate trial . Continuation hormonal replacement therapy allow . Peripheral neuropathy &gt; /= grade 2 History severe hypersensitivity reaction Docetaxel , Avastin , drug formulate polysorbate ( Tween ) 80 . Current , recent ( within 4 week first infusion study ) , plan participation experimental drug study Avastin Blood pressure &gt; 150/100 mmHg Unstable angina New York Heart Association ( NYHA ) Grade II great congestive heart failure History myocardial infarction within 6 month prior Day 1 History stroke within 6 month prior Day 1 Clinically significant peripheral vascular disease Evidence bleed diathesis coagulopathy Presence central nervous system brain metastasis Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 0 , anticipation need major surgical procedure course study Minor surgical procedure fine needle aspiration core biopsy within 7 day prior Day 0 Pregnant ( positive pregnancy test ) lactate Urine protein : creatinine ratio &gt; /= 1.0 screen History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior Day 0 Serious , nonhealing wound , active ulcer , untreated bone fracture Evidence malignancy last 5 year , nonmelanoma cutaneous carcinoma History hemoptysis ( bright red blood 1/2 teaspoon ) within last 3 month Patients believe possibly high average risk perforation exclude study . This include symptoms finding partial complete bowel obstruction , history fistula , patient require parenteral nutrition hydration , history prior perforation due tumor perforation within last 6 month cause . Inability comply study and/or followup procedure . Patients stable dose anticoagulation therapy . Patients stable anticoagulation regimen , include coumadin low molecularweight heparin , exclude .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>recurrent primary peritoneal cavity cancer</keyword>
	<keyword>recurrent fallopian tube cancer</keyword>
</DOC>